Abstract: A method for dissolving an arginineamide of the invention comprising dissolving N.sup.2 -arylsulfonyl-L-arginineamide having the general formula (I) ##STR1## wherein R.sup.1 represents a (2R, 4R)-4-alkyl-2-carboxypiperizino group and R.sup.2 represents a phenyl group or a condensed polycyclic compound residue which may be substituted with one or more substituents selected from lower alkyl groups, lower alkoxy groups and lower alkyl-substituted amino groups, said condensed polycyclic compound residue including a benzene ring which binds to sulfur atom of the sulfonyl group in the general formula (I) and is condensed with one or more other rings which may be heterocyclic and having 7 to 14 carbon atoms as the ring-constituent atoms;and/or its salt in a solvent of alcohol and water is disclosed herein.And, the pharmaceutical composition comprising N.sup.2 -arylsulfonyl-L-arginineamide having the general formula (I), an alcohol and water is disclosed herein.

Abstract: A soap composition comprising a blend of a solid soap base and a phospholipid is disclosed.

Abstract: A skin care base material for external use comprising a phospholipid, an ester of a fatty acid and a polyoxyethylene fatty acid ester is disclosed.

Abstract: Skin preparations containing a phosphatide, a topical corticosteroid, and butylhydroxyanisole and/or butylhydroxytoluene, which may be in the form of an aqueous or oily mixture, non-aqueous, water-soluble base or suspension base. These preparations can be applied to various skin diseases including eczema, lichen, ichthyosis and psoriasis, possess improved therapeutic activities and are stable for a prolonged period of time.

Abstract: Skin preparations containing a phosphatide, a topical corticosteroid, and butylhydroxyanisole and/or butylhydroxytoluene, which may be in the form of an aqueous or oily mixture, non-aqueous, water-soluble base or suspension base. These preparations can be applied to various skin diseases including eczema, lichen, ichthyosis and psoriasis, possess improved therapeutic activities and are stable for a prolonged period of time.

Abstract: Titanium minerals are concentrated by leaching with an acid leaching agent in the presence of a chelating agent, sulfonate surfactant or polyacrylamide surfactant, wherein the iron components are removed from the minerals.